JBM (Healthcare) Limited (2161.HK) Stock

About JBM (Healthcare) Limited

JBM (Healthcare) Limited, an investment holding company, engages in the manufacture, marketing, distribution, and sale of branded healthcare and wellness products in Hong Kong, Macau, Mainland China, Singapore, and internationally. It operates through Branded Medicines, Proprietary Chinese Medicines, and Health and Wellness Products segments. The Branded Medicines segment develops, manufactures, and distributes branded medicines with chemical compounds as active ingredients. The Proprietary Chinese Medicines segment develops, manufactures, and distributes registered Chinese medicines composed of Chinese herbal medicines. The Health and Wellness Products segment distributes and sells supplements, medical consumables, and other non-pharmaceutical products for the general health and wellness of consumers. The company also offers consumer healthcare and proprietary Chinese medicines, such as over-the-counter medicines, and CCMG products. It is also involved in the manufactures, trading, wholesaling, and retailing of Chinese medicines; trading of medical supplies and pharmaceutical products; and sale of healthcare and herbal products. The company was incorporated in 2020 and is headquartered in Kwun Tong, Hong Kong.

JBM (Healthcare) Limited (2161.HK) stock trades at $1.90 with a market capitalization of $1.55B. The stock is valued at a price-to-earnings (P/E) ratio of 7.58, price-to-book of 1.44, price-to-sales of 1.86. Over the past 52 weeks the stock has ranged between $1.84 and $3.15, and currently trades 39.7% below its 52-week high. It pays a dividend yielding 7.76%.

On profitability, JBM (Healthcare) Limited generates a return on equity (ROE) of 18.33%, above the typical market average, an operating margin of 29.21%, a net profit margin of 24.09%.

Official website: www.jbmhealthcare.com.hk